Treatment of dyslipidemia: Genetic interactions with diet and drug therapy

Current Atherosclerosis Reports

Volumn 1, Issue 1, 1999, Pages 16-23

  Ordovas, Jose M ^a   Schaefer, Ernst J ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

apoE Gene; Arterioscler Thromb Vasc Biol; Cholesteryl Ester Transfer Protein; Familial Hypercholesterolemia

Indexed keywords

APOLIPOPROTEIN; CARRIER PROTEIN; CETP PROTEIN, HUMAN; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; GLYCOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPID;

ARTICLE; BLOOD; GENETICS; HUMAN; HYPERLIPIDEMIA; LOW FAT DIET;

ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL ESTERS; DIET, FAT-RESTRICTED; GLYCOPROTEINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPIDS;

EID: 0033157009     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-999-0045-3     Document Type: Article

References (53)

1. Ordovas JM, Schaefer EJ: Genes, variation of cholesterol and fat intake and serum lipids. Curr Opin Lipidol 1999, 10:15–22. DOI: 10.1097/00041433-199902000-00004
2. Ordovas JM, Lopez-Miranda J, Perez-Jimenez F, et al.: Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 1995, 113:157–166. DOI: 10.1016/0021-9150(94)05439-P
3. Schaefer EJ, Lamon-Fava S, Ausman LM, et al.: Individual variability in lipoprotein cholesterol response to national cholesterol education program step 2 diets. Am J Clin Nutr 1997, 65:823–830.
4. Tall A, Welch C, Applebaum-Bowden D, Wassef M.: Interaction of diet and genes in atherogenesis. Report of an NHLBI working group. Arterioscler Thromb Vasc Biol 1997, 17:3326–3331.
5. Carmena R, Roederer G, Mailloux H, et al.: The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism. Metabolism 1993, 42:895–901. DOI: 10.1016/0026-0495(93)90066-W
6. Nemeth A, Szakmary KA, Kramer J, et al.: Apolipoprotein E and complement C3 polymorphism and their role in the response to gemfibrozil and low fat low cholesterol therapy. Eur J Clin Chem Clin Biochem 1995, 33:799–804.
7. Nestel P, Simons L, Barter P, et al.: A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apoE genotype, lipoprotein(a) and insulin. Atherosclerosis 1997, 129:231–239 DOI: 10.1016/S0021-9150(96)06031-5
8. Connor WE, Connor SL: Should a low-fat, high-carbohydrate diet be recommended for everyone? The case for a low-fat, high-carbohydrate diet. N Engl J Med 1997, 337:562–563; discussion 566–567. DOI: 10.1056/NEJM199708213370811
9. Katan MB, Grundy SM, Willett WC: Should a low-fat, high-carbohydrate diet be recommended for everyone? Beyond low-fat diets. N Engl J Med 1997, 337:563–566; discussion 566–567.
10. Rudel LL: Low-fat diets [abstract]. N Engl J Med 1998, 338:128.
11. Strain GW: Low-fat diets. N Engl J Med 1998, 338:128. DOI: 10.1056/NEJM199801153380305
12. Thompson PD: More on low-fat diets. N Engl J Med 1998, 338:1623–1624. DOI: 10.1056/NEJM199805283382212
13. Grundy SM: What is the desirable ratio of saturated, polyunsaturated, and monounsaturated fatty acids in the diet? Am J Clin Nutr 1997, 66:988S-990S.
14. Oliver MF: It is more important to increase the intake of unsaturated fats than to decrease the intake of saturated fats: evidence from clinical trials relating to ischemic heart disease. Am J Clin Nutr 1997, 66:980S-986S.
15. Stamler J, Greenland P, Van Horn L, Grundy SM: Dietary cholesterol, serum cholesterol, and risks of cardiovascular and non-cardiovascular diseases. Am J Clin Nutr 1998, 67: 488–492.
16. Lopez-Miranda J, Ordovas JM, Espino A, et al.: Influence of mutation in human apolipoprotein A-1 gene promoter on plasma LDL cholesterol response to dietary fat. Lancet, 1994, 343:1246–1249. DOI: 10.1016/S0140-6736(94)92149-0
17. Mata P, Lopez-Miranda J, Pocovi M, et al.: Human apolipoprotein A-I gene promoter mutation influences plasma low density lipoprotein cholesterol response to dietary fat saturation. Atherosclerosis 1998, 137:367–376. DOI: 10.1016/S0021-9150(97)00265-7
18. Carmena-Ramon RF, Ordovas JM, Ascaso JF, et al.: Influence of genetic variation at the apoA-I gene locus on lipid levels and response to diet in familial hypercholesterolemia. Atherosclerosis 1998, 139:107–113. DOI: 10.1016/S0021-9150(98)00064-1
19. Meng QH, Pajukanta P, Valsta L, et al.: Influence of apolipoprotein A-1 promoter polymorphism on lipid levels and responses to dietary change in Finnish adults. J Intern Med 1997, 241:373–378. DOI: 10.1046/j.1365-2796.1997.122139000.x
20. Ordovas JM, Cassidy DK, Civeira F, et al.: Familial apolipoprotein A-I, C-III and A-IV deficiency and premature atherosclerosis due to deletion of a gene complex on chromosome 11. J Biol Chem 1989, 264:16339–16342.
21. Mata P, Ordovas JM, Lopez-Miranda J, et al.: ApoA-IV phenotype affects diet-induced plasma LDL cholesterol lowering. Arterioscler Thromb 1994, 14:884–891.
22. McCombs RJ, Marcadis DE, Ellis J, Weinberg RB: Attenuated hypercholesterolemic response to a high-cholesterol diet in subjects heterozygous for the apolipoprotein A-IV-2 allele. N Engl J Med 1994, 331:706–710. DOI: 10.1056/NEJM199409153311104
23. Carmena-Ramon RF, Ascaso JF, Real JT, et al.: Rom Genetic variation at the ApoA-IV gene locus and response to diet in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1998, 18:1266–1274.
24. Jansen S, Lopez-Miranda J, Ordovas JM, et al.: Effect of 360His mutation in apolipoprotein A-IV on plasma HDL-cholesterol response to dietary fat. J Lipid Res 1997, 38:1995–2002.
25. Fisher RM, Burke H, Nicaud V, et al.: Effect of variation in the apoA-IV gene on body mass index and fasting and postprandial lipids in the European Atherosclerosis Research Study II. J Lipid Res 1999, 40:287–294.
26. Jansen S, Lopez-Miranda J, Salas J, et al.: Effect of 347-serine mutation in apoprotein A-IV on plasma LDL cholesterol response to dietary fat. Arterioscler, Thromb Vasc Biol 1997, 17:1532–1538.
27. Dallongeville J, Fruchart JC: Postprandial dyslipidemia: a risk factor for coronary heart disease. Annal Nutr & Metab 1998, 2:1–11. DOI: 10.1159/000012712
28. Lopez-Miranda J, Ordovas JM, Ostos MA, et al.: Dietary fat clearance in normal subjects is modulated by genetic variation at the apolipoprotein B gene locus. Arterioscler Thromb Vasc Biol 1997, 17:1765–1773.
29. Lopez-Miranda J, Jansen S, Ordovas JM, et al.: Influence of the SstI polymorphism at the apolipoprotein C-III gene locus on the plasma low-density-lipoprotein-cholesterol response to dietary monounsaturated fat. Am J Clin Nutr 1997, 66: 97–103.
30. Lefevre M, Ginsberg HN, Kris-Etherton PM, et al.: ApoE genotype does not predict lipid response to changes in dietary saturated fatty acids in a heterogeneous normolipidemic population. The DELTA Research Group. Dietary Effects on Lipoproteins and Thrombogenic Activity. Arterioscler Thromb Vascr Biol 1997, 17:2914–2923.
31. Sarkkinen E, Korhonen M, Erkkila A, et al.: Effect of apolipoprotein E polymorphism on serum lipid response to the separate modification of dietary fat and dietary cholesterol. Am J Clin Nutr 1998, 68:1215–1222.
32. Pasagian-Macaulay A, Aston CE, Ferrell RE, et al.: A dietary and behavioral intervention designed to lower coronary heart disease. Risk factors are unaffected by variation at the APOE gene locus. Atherosclerosis 1997, 132:221–227. DOI: 10.1016/S0021-9150(97)00091-9
33. Dixon LB, Shannon BM, Tershakovec AM, et al.: Effects of family history of heart disease, apolipoprotein E phenotype, and lipoprotein(a) on the response of children’s plasma lipids to change in dietary lipids. Am J Clin Nutr 1997, 66:1207–1217.
34. Lehtimaki T, Frankberg-Lakkala H, Solakivi T, et al.: The effect of short-term fasting, apolipoprotein E gene polymorphism, and sex on plasma lipids. Amer J Clin Nutr 1997, 66: 599–605.
35. Wolever TM, Hegele RA, Connelly PW, et al.: Long-term effect of soluble-fiber foods on postprandial fat metabolism in dyslipidemic subjects with apoE3 and apoE4 genotypes. Amer J Clin Nutr 1997, 66:584–590.
36. Yamashita S, Sakai N, Hirano K, et al.: Molecular genetics of plasma cholesteryl ester transfer protein. Curr Opin Lipidol 1997, 8:101–110. DOI: 10.1097/00041433-199704000-00008
37. Bruce C, Chouinard RA, Tall AR: Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. Annu Rev Nutr 1998, 18:297–330. DOI: 10.1146/annurev.nutr.18.1.297
38. Kondo I, Berg K, Drayna DT, Lawn RM: DNA polymorphism at the locus for human cholesteryl ester transfer protein (CETP) is associated with high density lipoprotein cholesterol and apolipoprotein levels. Clin Genet 1989, 35:49–56. DOI: 10.1111/j.1399-0004.1989.tb02904.x
39. Berg K, Kondo I, Drayna DT, Lawn RM: “Variability gene” effect of cholesteryl ester transfer protein (CETP) genes. Clin Genet 1989, 35:437–445. DOI: 10.1111/j.1399-0004.1989.tb02969.x
40. Drayna D, Lawn R: Multiple RFLP’s at the human cholesteryl ester transfer protein (CETP) locus. Nucleic Acids Res 1987, 15:4698. DOI: 10.1093/nar/15.11.4698
41. Dullaart RPF, Hoogenberg K, Riemens SC, et al.: Cholesteryl ester transfer protein gene polymorphism is a determinant of HDL cholesterol and of the lipoprotein response to a lipid lowering diet in type I diabetes. Diabetes 1997, 46: 2082–2087. DOI: 10.2337/diabetes.46.12.2082
42. Ojala J-P, Helve E, Ehnholm C, et al.: Effect of apolipoprotein E polymorphism and Xbal polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia. J Intern Med 1991, 230:397–405.
43. O’Malley JP, Illingworth DR: The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia. Metabolism 1990, 39:150–154. DOI: 10.1016/0026-0495(90)90068-N
44. de Knijff P, Stalenhoef AFH, Mol MJTM, et al.: Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 1990, 83:89–97. DOI: 10.1016/0021-9150(90)90134-5
45. Sanllehy C, Casals E, Rodriguez-Villar C, et al.: Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia. Metabol Clin Exp May 1999, 47:560–565.
46. Miettinen TA, Gylling H, Strandberg T, Sarna S: Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. BMJ 1998 1999, 316:1127–1130.
47. Kuivenhoven JA, Jukema JW, Zwinderman AH, et al.: The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998, 338:86–93. DOI: 10.1056/NEJM199801083380203
48. Goldstein MR: Polymorphism of the cholesteryl ester transfer protein gene. N Engl J Med 1999, 338:1624–5. DOI: 10.1056/NEJM199805283382213
49. Dullaart RP, Van Tol A: Polymorphism of the cholsteryl ester transfer protein gene. N Engl J Med 1999;338:1625–1626.
50. Vuorio AF, Ojala J-P, Sarna S, et al.: Heterozygous familial hypercholesterolaemia: the influence of the mutation type of the low-density-lipoprotein receptor gene and PvuII polymorphism of the normal allele on serum lipid levels and response to lovastatin treatment. J Intern Med 1995, 237: 43–48. DOI: 10.1111/j.1365-2796.1995.tb01138.x
51. Couture P, Brun LD, Szots F, et al.: Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous Familial Hypercholesterolemia. Arterioscler Thromb Vasc Biol 1998, 18:1007–1012.
52. Kajinami K, Yagi K, Higashikata T, et al.: Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in Familial Hypercholesterolemia. Am J Cardiol 1998, 82: 113–117. DOI: 10.1016/S0002-9149(98)00230-6
53. Yamada M.: Influence of apolipoprotein E polymorphism on bezafibrate treatment response in dyslipidemic patients. J Atheroscler Thromb 1997, 4:40–44.